LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
BREAKING: C2FO closes $200M investment led by backer of WeWork, Uber, Slack
Startup giant C2FO continues its climb to the top, having secured a new $200 million investment — and doubling the amount of its once-record funding raise in fewer than two years. “We are very fortunate to have a team who, for years, has delivered industry-leading unit economics, extraordinary customer satisfaction, and strong global growth,” Sandy…
As healthcare pivots to value based service, Helix Health uses data analytics to reduce costs
Prevention is cheaper than cure — a sentiment forming the foundation of Helix Health, said Anurag Patel. “The business of healthcare today is that if you’re sick, then you’re a customer of healthcare. If you’re healthy, then you’re not,” Patel said, describing a need for creating a business model that helps people stay healthy. Helix Health…
Watch: Tigersheep Friends creators build a ferociously off-beat, under-the-radar KC brand
From three-eyed leopards to strawberry cream giraffes, the creative minds behind Tigersheep Friends love illustrating off-beat versions of animals to keep their artistic passions alive, said Sarah Walsh. When the husband-and-wife duo started the company in 2011, they were looking for an alternate creative outlet, said Sarah Walsh, co-founder of the online product line. Click…
PayIt hires former Uber disruptive marketing leader as KC govtech startup’s first CMO
Kansas City-based govtech startup PayIt is downloading executive expertise from the West Coast, John Thomson said Tuesday, announcing PayIt’s first chief marketing officer — a former leader at Uber. Based in San Francisco, Alexandru Otrezov will lead PayIt’s marketing organization and continue to accelerate the company’s brand and growth efforts, said Thomson, co-founder and CEO…